Myriad Genetics Inc (Myriad) develops and commercializes molecular diagnostic products for cancer and arthritis. These diagnostic tests assess the person’s risk for disease development, disease progression and recurrence and guide through treatment decisions. It provides patient related critical information to physicians, enabling them to diagnose the disease at an early stage or delay the onset of the disease. It offers these diagnostic tests in three therapeutic areas such as oncology, women’s health, and mental Health. The company operates through one reportable segment.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

The company’s research and development are focused on therapy area related to oncology, urology, autoimmune, dermatology, mental health, and women’s health molecular diagnostic. The company focuses on the development of proprietary DNA sequencing and RNA expression technologies along with its supporting bioinformatics and robotic technologies. The company has R&D facilities located in Salt Lake City, South San Francisco, Texas, Ohio, in the US and Toronto, Ontario in Canada. In FY2022, the company has invested US$85.4 million on R&D related activities, which accounted for 12.6% of the company's annual revenue.